Section Arrow
Quote
OCGN.NASDAQ
- Ocugen
(Financial Status)
Quotes are at least 15-min delayed:2025/07/22 19:22 EDT
After Hours
Last
 1.04
+0.01 (+0.97%)
Bid
1.03
Ask
1.04
High 1.05 
Low 1.03 
Volume 30495 
Regular Hours
Last
 1.03
+0.02 (+1.98%)
Day High 
1.05 
Prev. Close
1.01 
1-M High
1.19 
Volume 
2.49M 
Bid
1.03
Ask
1.04
Day Low
0.99 
Open
1.02 
1-M Low
0.9029 
Market Cap 
294.95M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.07 
20-SMA 1.03 
50-SMA 0.96 
52-W High 1.6593 
52-W Low 0.515 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.20/-0.23
Enterprise Value
325.61M
Balance Sheet
Book Value Per Share
0.05
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
4.06M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.053+0.002+3.92%-- 
After Hours 0.0527 -0.0003 -0.57%
PLRZPolyrizon Ltd1.45+0.5422+59.73%-- 
After Hours 1.9 +0.45 +31.03%
REPLReplimune Group2.805-9.52-77.24%-- 
After Hours 2.79 -0.015 -0.53%
IOVAIovance Biotherapeutics3.13+0.64+25.70%-- 
After Hours 3.25 +0.12 +3.83%
TNFATNF Pharmaceuticals Inc.0.107-0.0224-17.31%-- 
After Hours 0.1086 +0.0016 +1.50%
Quotes are at least 15-min delayed：2025/07/22 19:22 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.